Aurinia Pharmaceuticals (NASDAQ:AUPH) CEO Kevin Tang Buys 264,981 Shares of Stock

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) CEO Kevin Tang purchased 264,981 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were acquired at an average price of $15.31 per share, with a total value of $4,056,859.11. Following the completion of the acquisition, the chief executive officer owned 12,494,481 shares of the company’s stock, valued at approximately $191,290,504.11. The trade was a 2.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Tang also recently made the following trade(s):

• On Tuesday, June 2nd, Kevin Tang purchased 206,005 shares of Aurinia Pharmaceuticals stock. The shares were acquired at an average price of $15.28 per share, with a total value of $3,147,756.40.
• On Monday, June 1st, Kevin Tang purchased 343,620 shares of Aurinia Pharmaceuticals stock. The shares were acquired at an average price of $15.28 per share, with a total value of $5,250,513.60.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $15.39 on Wednesday. Aurinia Pharmaceuticals Inc has a 1-year low of $7.28 and a 1-year high of $16.88. The firm has a market capitalization of $1.98 billion, a PE ratio of 7.09 and a beta of 1.41. The business’s 50 day moving average is $15.51 and its 200-day moving average is $15.25. The company has a current ratio of 5.55, a quick ratio of 5.01 and a debt-to-equity ratio of 0.08.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.07. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%.The company had revenue of $77.71 million for the quarter, compared to analyst estimates of $76.98 million. Sell-side analysts predict that Aurinia Pharmaceuticals Inc will post 0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, May 15th. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $17.25.

Institutional Trading of Aurinia Pharmaceuticals

Several institutional investors have recently modified their holdings of AUPH. JPMorgan Chase & Co. lifted its position in shares of Aurinia Pharmaceuticals by 21.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 533,290 shares of the biotechnology company’s stock worth $5,893,000 after buying an additional 94,941 shares during the period. Tudor Investment Corp ET AL acquired a new stake in Aurinia Pharmaceuticals in the 3rd quarter valued at $729,000. Ritholtz Wealth Management boosted its stake in Aurinia Pharmaceuticals by 206.2% in the 4th quarter. Ritholtz Wealth Management now owns 258,816 shares of the biotechnology company’s stock valued at $4,128,000 after buying an additional 174,301 shares in the last quarter. Navellier & Associates Inc. acquired a new stake in Aurinia Pharmaceuticals in the 3rd quarter valued at $926,000. Finally, SG Americas Securities LLC boosted its stake in Aurinia Pharmaceuticals by 69.6% in the 4th quarter. SG Americas Securities LLC now owns 136,224 shares of the biotechnology company’s stock valued at $2,173,000 after buying an additional 55,903 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.